GCTK Key Statistics, Chart & Performance
The current stock price of GCTK is 3.86 USD. In the past month the price decreased by -34.11%. In the past year, price decreased by -97.19%.
GCTK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.7 | 223.04B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.79 | 209.97B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.11 | 144.79B | ||
| SYK | STRYKER CORP | 27.71 | 139.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.24 | 58.61B | ||
| IDXX | IDEXX LABORATORIES INC | 56.01 | 56.40B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.47 | 49.92B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.94 | 39.61B | ||
| RMD | RESMED INC | 25.2 | 36.42B | ||
| DXCM | DEXCOM INC | 37.52 | 27.22B | ||
| PODD | INSULET CORP | 64.4 | 20.71B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.74 | 18.82B |
Related stock screener links
About GCTK
Company Profile
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Company Info
GLUCOTRACK INC
301 Rt 17 North, Suite 800
Rutherford NEW JERSEY US
Employees: 11
Phone: 197286757878
GLUCOTRACK INC / GCTK FAQ
What does GLUCOTRACK INC do?
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
What is the current price of GCTK stock?
The current stock price of GCTK is 3.86 USD. The price decreased by -2.03% in the last trading session.
Does GCTK stock pay dividends?
GCTK does not pay a dividend.
What is the ChartMill rating of GLUCOTRACK INC stock?
GCTK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What sector and industry does GLUCOTRACK INC belong to?
GLUCOTRACK INC (GCTK) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
How many employees does GLUCOTRACK INC have?
GLUCOTRACK INC (GCTK) currently has 11 employees.
GCTK Technical Analysis
GCTK Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |